NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-30 14:00இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Vimta Labs Q2 FY27 Total Income Up 9.9% YoY to ₹1,149 Mn; EBITDA Margin at 35.5%
Vimta Labs reported Q2 FY27 total income of ₹1,149 Mn (₹114.9 Cr), up 9.9% YoY and 1.8% QoQ. EBITDA for the quarter stood at ₹408 Mn, growing 10.5% YoY with EBITDA margins holding firm at 35.5%. Profit After Tax (PAT) rose 3.5% YoY to ₹206 Mn (margin at 17.9%), generating an EPS of ₹4.6. For H1 FY27, total income reached ₹2,278 Mn with a PAT of ₹417 Mn, aided by core pharma and food testing and initial revenue from biologics CRAD services.
உச்சம் நம்பிக்கை
என்ன மாறியதுVimta Labs reported its financial results for Q2 and H1 FY27, marking steady single-to-low-double-digit growth and initial commercial traction in biologics testing.
ஏன் இது முக்கியம்Demonstrates consistent operating margins above 35% despite modest bottom-line growth, signaling pricing power in high-end testing.
Total Income (Q2 FY27): ₹1,149 MnEBITDA Margin (Q2 FY27): 35.5%PAT (Q2 FY27): ₹206 MnH1 FY27 Total Income: ₹2,278 MnBasic EPS (Q2 FY27): ₹4.6
📅 குறுகிய காலம்Stable operational performance with flat sequential growth (PAT down 2% QoQ) is likely to result in neutral-to-muted market reaction.
📈 நீண்ட காலம்Entry into high-margin biologics CRAD services provides scientific breadth and supports management's ~20% medium-term structural growth aspirations.
⚠ அபாய எச்சரிக்கைகள்
PAT growth (3.5% YoY) is lagging behind revenue growth (9.9% YoY)
Sequential contraction in PAT (-2.0% QoQ) and EBITDA (-0.8% QoQ)
👀 கவனிக்க வேண்டியவை
Track the revenue scale-up from new biologics CRAD services and operational efficiency in H2 FY27 to see if PAT growth accelerates to match EBITDA expansion.
Vimta Labs Q2 FY27 Total Income Up 9.9% YoY to ₹114.9 Cr, PAT at ₹20.6 Cr
Vimta Labs released its Q2 & H1 FY27 investor presentation, reporting a Q2 total income of ₹1,149 Mn (up 9.9% YoY) and EBITDA of ₹408 Mn with a 35.5% margin. Q2 PAT rose 3.5% YoY to ₹206 Mn (₹20.6 Cr) with basic EPS at ₹4.6. For H1 FY27, total income reached ₹2,278 Mn with PAT of ₹417 Mn and EBITDA margin steady at 36.0%. The company maintains a strong balance sheet with cash and bank balances of ₹701 Mn against total debt of ₹144 Mn.
உச்சம் நம்பிக்கை
என்ன மாறியதுVimta Labs released its detailed operational and financial performance deck for Q2 & H1 FY27.
ஏன் இது முக்கியம்Demonstrates consistent ~35-36% operating margins and provides visibility on business diversification across pharma, food, and electronics testing.
📅 குறுகிய காலம்Stable operational performance with modest single-digit bottom-line growth expected to keep stock sentiment range-bound.
📈 நீண்ட காலம்Growth hinges on scaling large molecule/biologics services and defense electronics testing while utilizing existing ~600,000 sq. ft. capacity.
⚠ அபாய எச்சரிக்கைகள்
Moderation in YoY PAT growth (+3.5% in Q2 FY27)
Strict regulatory/GXP audit compliance dependency across international regulators
👀 கவனிக்க வேண்டியவை
Track the EBITDA margin sustainability in subsequent quarters and volume ramp-up across the biologics and electronics testing verticals.
13.7% YoY Revenue Growth in Q1 FY27; First Biologics Order Secured
Vimta Labs reported a resilient Q1 FY27 with total income reaching ₹112.9 cr, a 13.7% increase YoY. EBITDA margins remained strong at 36.4%, while PAT grew 11.4% YoY to ₹21.0 cr. A key milestone was securing the first order for the newly operationalized Biologics facility, marking entry into a high-margin segment. Management maintained a full-year growth guidance of 20-25%, despite geopolitical headwinds in the food testing export business.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from the investment phase to the operational phase in its Biologics business and integrated its environment division into the food division for operational efficiency.
ஏன் இது முக்கியம்Entry into Biologics and defense electronics testing represents a shift toward higher-value, specialized services which can sustain the company's industry-leading EBITDA margins (36.4%) and utilize the expanded 600,000 sq. ft. capacity.
Q1 FY27 Total Income: ₹112.9 கோடிYoY Revenue Growth: 13.7%EBITDA லாப வரம்பு: 36.4%PAT: ₹21.0 கோடிCash and Equivalents: ₹62.82 கோடிQ1 Revenue vs FY25 Annual Revenue: ~44%
📅 குறுகிய காலம்The stock may react positively to the margin expansion and the milestone of the first Biologics order, though seasonal Q4-to-Q1 flat sequential growth is noted.
📈 நீண்ட காலம்The company is structurally positioned for growth through its 600,000 sq. ft. lab capacity and diversification into high-growth areas like biologics and defense electronics.
👀 கவனிக்க வேண்டியவை
Watch for the revenue contribution and margin profile of the Biologics segment in upcoming quarters, and monitor if food export volumes recover from Middle East geopolitical disruptions.
13.7% YoY Revenue Growth in Q1 FY27; EBITDA Margins Expand to 36.4%
Vimta Labs reported a steady Q1 FY27 with total income rising 13.7% YoY to ₹112.9 crore. EBITDA grew 16% YoY to ₹41.1 crore, with margins expanding to 36.4% from 35.7% in the year-ago period. Net profit increased 11.4% YoY to ₹21.0 crore, supported by strong traction in Pharmaceutical Research and Testing. The company also operationalized its Biologics contract research and development services (CRADS) during the quarter, marking an entry into high-margin specialized segments.
உச்சம் நம்பிக்கை
என்ன மாறியதுVimta Labs reported its Q1 FY27 financial results and announced the commencement of operations in its Biologics CRADS division.
ஏன் இது முக்கியம்The results demonstrate the company's ability to maintain high operating margins (36%+) while diversifying into higher-value biologics services, which reduces reliance on the currently challenged food testing segment.
Total Income (Q1 FY27): ₹112.9 கோடிYoY Revenue Growth: 13.7%EBITDA லாப வரம்பு: 36.4%PAT (Q1 FY27): ₹21.0 கோடிQ1 வருவாய் vs TTM வருவாய்: 44.1%
📅 குறுகிய காலம்The stock may see positive sentiment due to double-digit revenue and profit growth alongside margin expansion in a challenging global environment.
📈 நீண்ட காலம்The expansion into Biologics and large molecule research is structurally significant as these segments typically offer higher pricing power and could drive long-term margin improvement.
⚠ அபாய எச்சரிக்கைகள்
Global uncertainties impacting the Food Testing division
Regulatory compliance risks inherent in clinical research services
👀 கவனிக்க வேண்டியவை
Watch for the revenue contribution and margin impact from the newly launched Biologics CRADS segment in upcoming quarters, and monitor the recovery of the food testing division which is currently facing global headwinds.
Vimta Labs Q1 FY27: 11.8% Revenue Growth to ₹109.07 Cr; PAT Rises to ₹21.04 Cr
Vimta Labs reported a steady performance for Q1 FY27, with revenue from operations increasing 11.8% YoY to ₹109.07 Cr. Net profit grew by 11.4% YoY to ₹21.04 Cr, maintaining a healthy Profit Before Tax (PBT) margin of 25.1%. The company continues to operate as a single-segment entity focused on Contract Research and Testing Services. Additionally, the board approved the grant of 40,500 ESOPs to eligible employees on July 20, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுVimta Labs released its Q1 FY27 financial results, showing consistent double-digit growth in revenue and profit compared to the previous year's corresponding quarter.
ஏன் இது முக்கியம்The results demonstrate the company's ability to maintain profitability and margins (PBT at 25%) while scaling its contract research operations, despite a slight sequential dip in revenue compared to Q4 FY26.
📅 குறுகிய காலம்The stock is likely to see neutral-to-positive sentiment as the results reflect steady execution and stable margins in line with historical performance.
📈 நீண்ட காலம்Long-term value depends on the company's ability to leverage its expanded infrastructure and pivot towards higher-margin specialized testing services like biologics and defense electronics.
⚠ அபாய எச்சரிக்கைகள்
Rising employee and operational costs
Regulatory compliance risks inherent in USFDA/GXP audited facilities
👀 கவனிக்க வேண்டியவை
Investors should monitor the utilization levels of the recently expanded 600,000 sq. ft. lab capacity and the growth trajectory in high-margin biologics and defense electronics testing.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
₹2 per share dividend paid for FY 2025-26 by Vimta Labs
Vimta Labs Limited has completed the payment of its final dividend for the financial year 2025-26. The dividend of ₹2 per equity share (face value ₹2) was distributed to eligible shareholders on July 4, 2026, following approval at the Annual General Meeting. Based on the TTM EPS of ₹22.07, this represents a dividend payout ratio of approximately 9%. The company continues to maintain a strong balance sheet with a debt-to-equity ratio of 0.01.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from the recommendation stage to the actual disbursement of the FY26 dividend to shareholders.
ஏன் இது முக்கியம்The payment confirms the company's commitment to shareholder returns while operating with high margins (OPM 34.1%) and minimal debt (₹3 Cr).
Dividend per share: ₹2Face Value: ₹2Payment Date: 04 ஜூலை 2026Dividend Payout Ratio (TTM): ~9.06%
📅 குறுகிய காலம்Neutral, as the dividend payment was previously recommended and expected by the market; no immediate impact on stock price is anticipated from this procedural update.
📈 நீண்ட காலம்Limited; the consistent dividend payment reflects financial stability but the long-term value remains tied to the expansion into defense electronics and biologics testing.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's utilization of its expanded 600,000 sq. ft. lab capacity in upcoming quarterly results to see if it translates to the targeted 20% growth rate.
Vimta Labs Shareholders Approve Rs 2 Dividend and Key Leadership Re-appointments at 36th AGM
Vimta Labs Limited successfully concluded its 36th Annual General Meeting on June 25, 2026, with all proposed resolutions receiving overwhelming shareholder approval. A key outcome for investors is the approval of a Rs 2 per equity share dividend for the financial year ended March 31, 2026. Shareholders also confirmed the re-appointment of Dr. S.P. Vasireddi as Executive Chairman and Mr. Harriman Vungal as Executive Director Operations, ensuring leadership continuity. The voting results showed strong consensus, with most resolutions passing with over 99.99% of votes in favor.
முக்கிய அம்சங்கள்
Approved a dividend of Rs 2 per equity share for the financial year ended March 31, 2026.Dr. S.P. Vasireddi re-appointed as Executive Chairman via special resolution with 99.99% favor.Mr. Harriman Vungal re-appointed as Executive Director Operations with 99.99% favor.Total of 17,103,073 votes were polled out of 44,669,355 total shares held.Ratification of cost auditors' remuneration for FY 2024-25 and FY 2025-26 was approved.
👀 கவனிக்க வேண்டியவை
Investors can expect the confirmed dividend payout of Rs 2 per share following this approval. The high level of shareholder support for management indicates strong confidence in the company's current strategic direction.
Vimta Labs to Hold 36th AGM on June 25, 2026; Proposes ₹2 Dividend and Leadership Re-appointments
Vimta Labs has scheduled its 36th Annual General Meeting for June 25, 2026, to approve the financial statements for FY 2025-26 and a proposed dividend of ₹2 per equity share. A key resolution includes the re-appointment of Dr. S P Vasireddi as Executive Chairman for a five-year term starting July 1, 2026, with a monthly salary of ₹18 lakh. The board also seeks ratification for cost auditor remuneration of ₹50,000 per annum for FY25 and FY26. Leadership continuity is emphasized with the re-appointment of Mr. Harriman Vungal as Executive Director of Operations.
முக்கிய அம்சங்கள்
Proposed dividend of ₹2 per equity share for the financial year ended March 31, 2026Re-appointment of Dr. S P Vasireddi as Executive Chairman for a 5-year term with a monthly salary of ₹18,00,000Executive Chairman's commission capped at 1% of Net Profits as per Section 198 of the Companies ActRatification of ₹50,000 annual remuneration for Cost Auditors M/s Lavanya and Associates LLP36th AGM to be conducted via Video Conferencing on June 25, 2026, at 10:00 A.M. IST
👀 கவனிக்க வேண்டியவை
Investors should monitor the AGM outcomes for confirmation of the ₹2 dividend and the long-term leadership stability provided by the Chairman's re-appointment. The continuity in management and consistent dividend payout are positive indicators for long-term shareholders.
Vimta Labs FY26 Revenue Up 19.5% to ₹4,163 Million; EBITDA Margins Strong at 35.8%
Vimta Labs reported a robust financial performance for FY26, with total income rising 19.5% YoY to ₹4,163 million and PAT increasing 16.1% to ₹775 million. The company maintained industry-leading profitability with an annual EBITDA margin of 35.8%, driven by strong demand in pharmaceutical and food testing segments. For Q4 FY26, revenue grew 16.6% YoY to ₹1,120 million, while quarterly EBITDA margins reached 37.6%. The company remains net debt-free with cash reserves of ₹650 million and is strategically expanding into biologics contract research for FY27.
முக்கிய அம்சங்கள்
FY26 total income grew by 19.5% YoY to ₹4,163 million, with Q4 income rising 16.6% to ₹1,120 million.Full-year EBITDA stood at ₹1,489 million with a healthy margin of 35.8%, among the best in the industry.Net profit (PAT) for the full year increased by 16.1% to ₹775 million, resulting in an EPS of ₹17.4.Maintained a net debt-free balance sheet with cash and bank balances of approximately ₹650 million.Announced strategic entry into biologics and peptides contract research services starting in FY27.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful transition into high-growth biologics and its ability to sustain high margins despite global cost pressures. The debt-free status and strong cash position provide a solid cushion for future capacity expansions.
Vimta Labs Re-appoints Founder Dr. S. P. Vasireddi as Executive Chairman for 5-Year Term
Vimta Labs has recommended the re-appointment of its founder, Dr. S. P. Vasireddi, as Executive Chairman for a five-year term effective from July 1, 2026, to June 30, 2031. As Dr. Vasireddi is 77 years old, the appointment requires a special resolution from shareholders at the upcoming Annual General Meeting. He currently holds a significant stake of 51,97,050 equity shares in the company. This move signals leadership continuity, as he has been pivotal to the company's growth for over four decades and is the father of the current Managing Director.
முக்கிய அம்சங்கள்
Re-appointment of Dr. S. P. Vasireddi as Executive Chairman for a 5-year term starting July 2026.Dr. Vasireddi holds 51,97,050 equity shares in Vimta Labs Limited.Special resolution required for appointment as the candidate has attained 77 years of age.Dr. Vasireddi has over 40 years of industry experience and founded the company.He is the father of the current Managing Director, Ms. Harita Vasireddi, ensuring family leadership continuity.
👀 கவனிக்க வேண்டியவை
Investors should see this as a positive sign of leadership stability and continuity of the founder's vision. No immediate action is required other than noting the upcoming shareholder vote on the special resolution.
Vimta Labs Recommends ₹2 Dividend per Share; Sets Record Date for June 18, 2026
Vimta Labs has recommended a final dividend of ₹2 per equity share for the financial year 2025-26. This payout represents a 100% dividend on the face value of ₹2 per share. The company has designated June 18, 2026, as the record date to identify eligible shareholders for this payment. Subject to shareholder approval at the Annual General Meeting, the dividend will be disbursed on or before July 8, 2026.
முக்கிய அம்சங்கள்
Recommended a dividend of ₹2 per equity share for the financial year 2025-26.The dividend payout is 100% of the face value of ₹2 per share.Record date for determining shareholder eligibility is June 18, 2026.Payment of dividend is scheduled to be completed on or before July 8, 2026.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should hold the stock prior to the ex-dividend date to be eligible for the ₹2 per share payout. The 100% dividend reflects the company's consistent policy of sharing profits with its shareholders.
Vimta Labs Recommends Final Dividend of ₹2 Per Share for FY 2025-26
Vimta Labs Limited has recommended a final dividend of ₹2 per equity share for the financial year 2025-26. The dividend is declared on shares with a face value of ₹2 each, representing a 100% payout on the nominal value. The company has fixed June 18, 2026, as the record date to identify eligible shareholders. Subject to shareholder approval at the upcoming AGM, the dividend is expected to be paid by July 8, 2026.
முக்கிய அம்சங்கள்
Recommended final dividend of ₹2 per equity share for FY 2025-26Dividend payout represents 100% of the face value of ₹2 per shareRecord date for dividend eligibility is fixed as June 18, 2026Payment to be processed on or before July 8, 2026, post-AGM approval
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the shares before the record date of June 18, 2026. The 100% dividend on face value indicates a stable return for long-term shareholders.
Vimta Labs FY26 Revenue Up 19.5% to Rs 4,163 Mn; Q4 PAT Rises 15.2% YoY
Vimta Labs reported a strong performance for FY26, with total income reaching Rs. 4,163 Mn, a 19.5% increase over the previous fiscal year. The company achieved its highest-ever quarterly revenue of Rs. 1,120 Mn in Q4 FY26, driven by growth in its Pharma and Food divisions. EBITDA margins remained robust at 35.8% for the full year, while annual PAT grew 16.1% to Rs. 775 Mn. Following the divestment of its diagnostics business in late 2024, the company has successfully focused on high-margin contract research and testing services.
முக்கிய அம்சங்கள்
Full-year FY26 revenue grew 19.5% YoY to Rs. 4,163 Mn compared to Rs. 3,482 Mn in FY25.Q4 FY26 EBITDA margin expanded to 37.6% compared to 34.3% in the preceding quarter.Annual Profit After Tax (PAT) increased to Rs. 775 Mn with a healthy margin of 18.6%.Basic EPS for the full year improved to Rs. 17.4 from Rs. 15.0 in the previous year.The company achieved its highest-ever quarterly revenue of Rs. 1,120 Mn in Q4 FY26.
👀 கவனிக்க வேண்டியவை
Investors should note the consistent margin profile and double-digit revenue growth as signs of strong operational execution in the CRO space. The stock remains a key player to watch in the testing and research sector following its successful pivot away from diagnostics.
Vimta Labs Reports Strong FY26 Performance with 19.5% Revenue Growth and 37.6% Q4 EBITDA Margin
Vimta Labs Limited delivered a robust financial performance for FY26, with total income rising 19.5% YoY to ₹4,163 million. The company maintained strong profitability, reporting a full-year PAT of ₹775 million and an EPS of ₹17.4. Operational efficiency was particularly notable in Q4, where EBITDA margins reached 37.6%. With a very low debt-to-equity ratio of 0.01 and cash reserves of ₹650.6 million, the company is well-positioned for its ongoing expansion plans.
முக்கிய அம்சங்கள்
Total Income for FY26 grew 19.5% YoY to ₹4,163 million, while Q4 income rose 16.6% YoY to ₹1,120 million.Q4 EBITDA margins improved to 37.6% compared to 36.1% in the same quarter last year.Full-year PAT increased by 16.1% to ₹775 million, supported by growth across Pharma, Food, and Electronics testing segments.The company undertook a significant Capex of ₹998 million in FY26 to enhance lab infrastructure and capabilities.Balance sheet remains exceptionally strong with total debt of only ₹33.3 million against cash equivalents of ₹650.6 million.
👀 கவனிக்க வேண்டியவை
Investors should note the company's consistent margin profile and minimal leverage as signs of high-quality growth. The aggressive capex cycle indicates strong future demand in the TIC (Testing, Inspection, and Certification) sector, making it a solid long-term hold.
Vimta Labs FY26 Equity Grows 20%; Announces ₹2 Dividend and US Subsidiary Incorporation
Vimta Labs reported a strong balance sheet for the financial year ended March 31, 2026, with total equity rising to ₹4,568.73 million from ₹3,788.48 million in the previous year. The Board has recommended a dividend of ₹2 per share (100% of face value) and approved the incorporation of a wholly-owned subsidiary in the USA to drive international expansion. Leadership stability is also addressed with the reappointment of Dr. S. P. Vasireddi as Executive Chairman for a five-year term starting July 2026.
முக்கிய அம்சங்கள்
Recommended a dividend of ₹2 per share (100% on face value of ₹2) for FY 2025-26.Total Assets increased by 20.5% year-on-year to ₹5,622.28 million as of March 31, 2026.Approved the incorporation of a new wholly-owned subsidiary in the USA to expand global operations.Reappointed Dr. S. P. Vasireddi as Executive Chairman for a 5-year term (2026-2031).Total Equity and Reserves rose significantly to ₹4,568.73 million from ₹3,788.48 million.
👀 கவனிக்க வேண்டியவை
Investors should view the US expansion and consistent dividend payout as signs of management's growth confidence; the stock remains a solid hold for long-term value.
Vimta Labs Q3 FY26 Revenue Up 10.2% YoY to ₹100.5 Cr; 9M Profit Grows 16.4%
Vimta Labs reported a 10.2% YoY revenue growth in Q3 FY26, reaching ₹100.5 crores, although it experienced a 3.9% sequential decline due to operational restructuring and clinical order lags. The 9-month performance remains strong with total income rising 20.7% to ₹304.3 crores and PAT increasing 16.4% to ₹56.4 crores. The company is expanding into biologics CRDMO services, expected to commercialize in Q1 FY27, and maintains a net debt-free balance sheet. Management expects a stronger Q4 performance, aligning with historical seasonal trends.
முக்கிய அம்சங்கள்
Q3 FY26 revenue grew 10.2% YoY to ₹100.5 crores, while 9M FY26 revenue rose 20.7% to ₹304.3 crores.EBITDA for 9M FY26 stood at ₹106.8 crores with a healthy margin of 35.1%.Recognized a one-time exceptional cost of ₹1.6 crores due to new labor law implementation.Biologics contract research and development services are scheduled for commercialization by Q1 FY27.EMI/EMC testing facility is operating at 80-85% utilization, with a second chamber installation on track.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful commercialization of the biologics segment in FY27 and the recovery of clinical research order bookings. The company's debt-free status and strong margins in the TIC sector provide a stable long-term outlook.
Vimta Labs Q3 FY26 Total Income Rises 10.2% YoY to ₹1,005 Mn; PAT Flat at ₹176 Mn
Vimta Labs reported a 10.2% YoY increase in total income for Q3 FY26, reaching ₹1,005 million, though revenue declined 3.9% on a sequential basis. Net profit remained nearly flat YoY at ₹176 million, with margins facing pressure as the EBITDA margin contracted to 34.3% from 37.6% in the previous year. The margin compression was partly attributed to exceptional items related to the impact of New Labour Codes. However, the nine-month (9M FY26) performance remains robust, with total income growing 20.7% and PAT increasing 16.4% YoY.
முக்கிய அம்சங்கள்
Total Income for Q3 FY26 stood at ₹1,005 Mn, up 10.2% YoY but down 3.9% QoQ.EBITDA margin contracted to 34.3% in Q3 FY26 compared to 37.6% in Q3 FY25.9M FY26 Total Income grew significantly by 20.7% YoY to ₹3,043 Mn.Net Profit for 9M FY26 increased by 16.4% YoY to ₹564 Mn with an EPS of ₹12.67.Margins were impacted by exceptional costs related to the implementation of New Labour Codes.
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of the New Labour Codes on future margins to see if the current compression is transitory. While the 9-month growth trajectory is strong, the sequential dip in revenue and profit warrants a cautious watch on near-term demand.
Vimta Labs Q3 FY26: Revenue Grows 9.7% YoY to ₹986M; PAT Steady at ₹176M
Vimta Labs reported a 9.7% YoY growth in revenue from operations for Q3 FY26, reaching ₹986.33 million. Net profit from continuing operations remained nearly flat at ₹175.86 million compared to ₹175.16 million in the previous year, largely due to a one-time exceptional charge of ₹16.16 million related to the implementation of new labour codes. For the nine-month period, the company showed stronger performance with revenue increasing 19.4% and net profit rising 16.4% YoY. The company continues to focus on its core contract research and testing services following the divestment of its diagnostics business.
முக்கிய அம்சங்கள்
Revenue from operations increased to ₹986.33 million in Q3 FY26 from ₹899.23 million in Q3 FY25.Net profit for the quarter stood at ₹175.86 million, including a ₹16.16 million exceptional cost for gratuity adjustments under new labour codes.9M FY26 total income reached ₹3,042.83 million, a significant jump from ₹2,521.41 million in the same period last year.Basic EPS for the quarter was ₹3.96, compared to ₹3.93 in the year-ago period (adjusted for the 1:1 bonus issue).The Board approved the grant of 38,269 new ESOP options to eligible employees.
👀 கவனிக்க வேண்டியவை
The steady revenue growth in the core testing business is positive, though margins were temporarily impacted by statutory exceptional items. Long-term investors should monitor the scalability of the National Food Testing Laboratory (PPP project) and the impact of labour code revisions on operating margins.
Vimta Labs Q3 Net Profit at ₹175.86 Mn; 9M Revenue Grows 19% YoY
Vimta Labs reported a steady Q3 FY26 with revenue from operations reaching ₹986.33 million, a 9.7% growth compared to the same quarter last year. Net profit for the quarter stood at ₹175.86 million, which remained relatively flat YoY due to a one-time exceptional charge of ₹16.16 million related to new labor code compliance. For the nine-month period ending December 2025, the company showed robust performance with total income rising to ₹3,042.83 million from ₹2,521.41 million in the previous year. The company has successfully transitioned its focus to core contract research and testing services following the divestment of its diagnostic business.
முக்கிய அம்சங்கள்
Revenue from operations for Q3 FY26 grew 9.7% YoY to ₹986.33 million.Net Profit for the nine-month period (9M FY26) increased by 16.4% to ₹563.99 million.Recorded a one-time exceptional expense of ₹16.16 million for gratuity adjustments under new labor codes.Basic EPS for the quarter stood at ₹3.96, adjusted for the 1:1 bonus issue completed in June 2025.The Board approved the grant of 38,269 new ESOP options to eligible employees.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain margins in its core testing segment now that the lower-margin diagnostic business has been divested. The steady YoY growth in the nine-month period suggests a positive trajectory for the core business.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
